Drops, Drops, and More Drops by John Walt & Fern Alexander
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
12 
 Drops, Drops, and More Drops 
John Walt1 and Fern Alexander2 
1Allergan, Inc., Irvine, CA,  
2WordScapes, El Dorado, CA,  
USA 
“If we could help patients with glaucoma take their drops better, it would be like doubling 
the effect of their treatment—the equivalent of adding a second drop.” 
(Harry A. Quigley, 2008) 
1. Introduction 
Glaucoma is the second leading cause of blindness worldwide. (Quigley & Broman, 2006) In 
undeveloped countries, both limited detection and inadequate treatment contribute to the 
high prevalence (20%) of blindness from glaucoma. (Leske et al., 2004) Yet, even in 
developed nations, where treatment is available and accessible for most of those who have 
been diagnosed, treatment adherence and persistence remain formidable obstacles to 
forestalling glaucoma progression. (Schwartz and Quigley, 2008) 
In the last few years, researchers have shown that medical treatment can delay or halt the 
progression of glaucoma, and that early identification and treatment are vital to preserving 
vision. (Kass et al., 2002; Kass et al., 2010; Musch et al., 2009) Despite the characterization of 
glaucoma as a degenerative neuropathy of the optic nerve, lowering intraocular pressure 
(IOP) by regulating the volume of the aqueous humor remains the mainstay of treatment. 
The Advanced Glaucoma Intervention Study (AGIS) was one of the first to demonstrate that 
lowering IOP protects against visual field deterioration. (AGIS, 2000) Subsequently, the 
Ocular Hypertension Treatment Study (OHTS) revealed that topical medication can reduce 
IOP by 22.5% in those at risk of developing glaucoma, thereby preventing the onset of 
primary open angle glaucoma (POAG) in the majority of at-risk patients with elevated IOP. 
(Kass et al., 2002) Several studies demonstrated that early treatment produced better visual 
outcomes than when treatment was delayed. (Musch et al., 2009; Kass et al., 2010) 
Paradoxically, however, this is the most challenging time during the course of the disease 
with regard to treatment adherence. Most patients are asymptomatic early in the disease, 
and if they do not perceive an immediate benefit from using their eye drops, they are less 
likely to use them. (DiMatteo et al., 2002) 
Drops are the liquid equivalent of a pill, and measure a discrete quantity of medication in a 
specified volume, as a means of delivering the prescribed amount of drug. While drops are a 
convenient method for specifying dosage, the fluid nature of the liquid state implies that 
drops are more easily divisible than a solid pill. Whereas effort and intention are required to 
subdivide a pill, drops less readily retain their integrity, allowing volume to be 
unintentionally sacrificed. Indeed, several variables can affect the size of the drop that is 
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dispensed. (Fiscella et al., 2006) When patients receive a prescription for 30 pills and are 
instructed to take one-a-day for one month, there is little room for misunderstanding. A 
bottle of ophthalmic drops in contrast presents surprising confusion for patients and 
physicians alike. This chapter sheds some light on the complexities of ophthalmic solutions. 
Conventional treatment usually begins with topical medications, since they are equally as 
effective as surgical or laser treatment, and their noninvasiveness imposes less risk. (Musch 
et al., 2009) At some point, if medical options are unsuccessful at lowering IOP, surgery may 
be considered. Several types of topical glaucoma medications are used in conventional 
treatment. First-line therapy includes the prostaglandin/prostamide analogs (PGAs) 
(bimatoprost, travoprost, lanatoprost), favored for their once-daily dosing, effective 
lowering of IOP, and low side effect profile. (McKinnon et al., 2008; Clark and Yorio, 2003; 
Chan et al., 2007) They lower IOP by increasing the outflow of aqueous humor. Some of 
these may also be used in fixed combination with timolol. Other first-line treatments, 
including cardioselective beta-adrenergic (betaxolol) or noncardioselective beta-adrenergic 
receptor blockers (timolol), act by reducing aqueous humor formation. Beta-blockers, which 
also reduce aqueous humor formation, are administered once or twice daily and have few 
ocular side effects. However, they may cause adverse respiratory, cardiac or central nervous 
system effects. Brimonidine, an alpha-adrenergic blocker, and dorzolamide, a carbonic 
anhydrase inhibitor, can be used as monotherapy and are also used as adjunctive therapy in 
fixed combinations with timolol. (Chan et al., 2007; Woodward and Chen, 2007; 
Higginbotham, 2010; Khouri et al., 2009) 
2. Adherence and persistence are vital elements of treatment 
The inverse relationship between treatment and progression highlights the importance of 
both adherence and persistence with the prescribed medical treatment. Adherence and 
persistence refer to 2 distinct aspects of treatment with eye drops, although they are often 
inextricably linked. Adherence, which has also been called compliance, refers to how closely 
the patient follows the prescribed dosing regimen. (Schwartz & Quigley, 2008) Persistence, 
on the other hand, refers to the duration of treatment—the ability to sustain the dosing 
regimen on a long-term basis. It is defined as the length of time until the patient first 
discontinues the medication. For example, a patient who fills the first 3 months of 
prescriptions, but does not renew the prescription the fourth month is referred to as being 
persistent for 3 months, even if the prescription is filled at some later time. 
Both adherence and persistence are essential for preserving vision by ensuring the regular 
delivery of the correct amount of medication to maintain lower intraocular pressure (IOP), 
thereby reducing the risk of permanent damage to the optic nerve. 
3. Factors that impact adherence and persistence 
Adherence and persistence are multi-faceted phenomena in the clinical setting. They are 
sensitive to the affects of tolerability, cost, scheduling, difficulty administering eye drops, 
denial, educational level, and forgetfulness. (Schwartz and Quigley, 2008) 
One obvious challenge to adherence is the uncomfortable and/or unsightly side effects of 
eye drops, such as stinging, burning, dry eye, tearing, and hyperemia that can discourage 
patients from continuing treatment. The most frequently prescribed medications 
demonstrate similar levels of tolerability. (Beckers et al., 2008) Poor tolerability contributes 
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to a measurable treatment burden for glaucoma, which has been documented in health-
related quality of life (HRQOL) studies. (Bechetoille et al., 2008) Once patients begin 
treatment for ocular hypertension, burden of treatment is the most affected domain on the 
Glau-QOL, a glaucoma-specific quality-of-life questionnaire, and it is unrelated to visual 
impairment. The prevalence of intolerable side effects is not inconsequential among 
glaucoma patients using eye drops. Between 14% and 25% of patients reported troubling 
side effects. (Schwartz and Quigley, 2008; Sleath et al., 2006; Odberg et al., 2001) Patients 
who need multiple medications have more difficulty with adherence than those on 
monotherapy. (Schwartz and Quigley, 2008) The necessity for dosing a single medication 
several times daily, or for using multiple medications with complex dosing schedules adds 
another layer of complexity that discourages adherence. (Busche and Gramer, 1997; Djafari 
et al., 2009)  Patients can simply forget to administer their drops because it is not integrated 
into their routine, or they may fail to bring the drops when they are away from home. 
Several challenges to adherence are unique to the use of eye drops. Unlike taking an oral 
medication, the instillation of eye drops requires a dexterity that many patients lack, 
especially the elderly. Consequently, 44% of glaucoma patients have reported difficulty 
administering their eye drops, and between 13% to 33% of patients rely on others to instill 
them. (Schwartz and Quigley, 2008; Sleath et al., 2006; Burns and Mulley, 1992) In addition 
to dexterity, the instillation of eye drops requires procedural attention to ensure that the tip 
of the bottle does not touch the eye or other surfaces, and that the drop is actually delivered 
into the eye, rather than dripped down the face. The correct procedure for instilling the 
drops is often not demonstrated to patients, and their instillation techniques may not be 
observed by the clinician. In a Canadian study, 7% of patients missed their eye completely, 
and 29% contaminated the bottle tip. (Kholdebarin et al., 2008) 
Psychological factors associated with glaucoma also can impact the adherence rate. 
Glaucoma patients are at increased risk of depression, especially as HRQOL declines and/or 
the disease progresses. (Skalicky and Goldberg, 2008; Tastan et al., 2010) Depression has 
been shown to be associated with nonadherence. (Friedman et al., 2009; Pappa et al., 2006) 
Pappa et al. demonstrated that 42% of glaucoma patients were nonadherent, omitting at 
least 2 doses per week. (Pappa et al., 2006)  Nonadherence was directly associated with 
disease duration (P <.05), frequency of dosing, and an increase in disease severity, but not 
with the type of medication prescribed. Depression in glaucoma was independently shown 
to be unrelated to the use of topical beta-blockers. (Wilson et al., 2002; Kaiserman et al., 2006; 
Mabuchi et al., 2008) 
A vicious cycle often exists with regard to the impact of assessing adherence on clinical 
decision making. While early detection and treatment to lower IOP are essential for 
preserving the integrity of the optic nerve and visual function, these are jeopardized by poor 
adherence resulting from the imperceptible benefit of treatment. The lack of incentive this 
engenders ultimately leads to therapeutic failure and disease progression. This situation is 
compounded by the tendency of patients to overestimate their adherence with eye drops 
when questioned by their physician due to recall bias and the desire to please the physician. 
(Freidman et al., 2005; Friedman et al., 2008; Schwartz and Quigley, 2008) The inaccuracy of 
adherence self-report, whether by self-administered questionnaire or verbally, may also be 
due to white-coat adherence, a well-recognized phenomenon whereby patients improve 
their adherence 5 days before and after an office visit. (Tsai, 2006; Feinstein, 1990; Cramer et 
al., 1990; Okeke et al., 2009a) Consequently, it is difficult for physicians to assess the verity 
of adherence reports by every patient, although the accuracy of this information is vital for 
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determining the course of treatment. (Schwartz and Quigley, 2008; Kass et al., 1986) Even in 
the landmark Glaucoma Adherence and Persistence Study (GAPS), where adherence was 
measured in 3 different ways—by verbal self-report, administrative claims data, and chart 
review—to cross-reference and compare accuracy, 95% of patient self-reports overestimated 
adherence, despite objective evidence to the contrary. (Quigley, 2008) 
A physician clinically evaluating IOP and disease progression cannot distinguish between 
whether the elevated IOP is caused by failure to take the medication or by ineffectiveness of 
the currently prescribed regimen. If the patient claims to be adherent, then the physician 
will assume that the current regimen is inadequate and escalate treatment. This, in and of 
itself, can lead to a vicious cycle, because more complex regimens with multiple medications 
may present an even greater challenge to adherence. (Tsai, 2006; Higginbotham, 2010) 
Intermittent dosing will not lead to sustained lowering of IOP, and deterioration of the 
visual field may increase. If the patient presents at the next visit with an optimal IOP, but 
there is evidence of visual field progression, it is impossible to distinguish whether the 
target IOP needs to be lowered by adding therapy, or if the target IOP is appropriate and the 
progression is due to nonadherence. (Schwartz and Quigley, 2008) 
 
Medication Regimen-Related Factors 
Side effects 
Cost 
Complicated dosing regimen 
Multiple glaucoma medications 
Patient-Related Factors 
Forgetfulness 
Depression 
Denial that disease will progress to blindness 
Poor dexterity 
Poor vision 
Low motivation 
Comorbidity 
Poor adherence to office visits 
Health literacy 
Provider-Related Factors 
Mistrust of physician 
Quality of the patient-physician relationship 
Provides insufficient patient education 
Poor communication 
Patient dissatisfaction with the level of care received 
Environmental Factors 
Forgetting to bring them when traveling 
Inconvenience 
Inability to perceive effects of medication 
Table 1. Factors that Affect Adherence 
Numerous additional reasons have been cited for poor adherence. One study identified 71 
reasons why patients do not adhere; these were ascribed to 4 categories: regimen-related 
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factors, patient-related factors, provider-related factors, and situational/environmental 
factors. (Tsai, 2006; Tsai et al., 2003) Regimen-related factors include cost, complexity, and 
side effects. Patient-related factors include memory, health literacy, motivation, and 
comorbidity. Provider-related factors include poor communication from the provider 
regarding the prescription or the patient’s dissatisfaction with the level of care received. 
Situational or environmental factors relate primarily to challenges in the logistics of the 
patient’s routine. (See Table 1) All told, the rate of adherence to glaucoma medications is 
reported to vary between 24% and 80% (depending upon the study), an extremely low rate 
that largely contributes to disease progression, considering that pharmacologic therapies are 
capable of preventing or delaying disease progression when given the opportunity. 
(Rotchford and Murphy, 1998; Gurwitz et al., 1993; Patel and Spaeth, 1995; Olthoff et al., 
2005) In a study of elderly glaucoma patients on Medicaid, in which the overall adherence 
rate was 77%, factors associated with nonadherence included the use of glaucoma 
medication that required more than 2 administrations per day, and the presence of multiple 
medications in the patient’s drug regimen. (Gurwitz et al., 1993)  Paradoxically, the factors 
shown to be most important to glaucoma patients are long-term blindness (important to 
38%) and the risk of moderate visual loss (27%), although a large percentage of patients are 
unwilling or unable to do what is necessary to prevent these. (Bhargava et al., 2006) Yet, 
knowledge of the potential consequences of glaucoma, including blindness, is similar 
between adherent (85%) and nonadherent (88%) patients. (Tsai, 2009; Kosoko et al., 1998) 
One of the most important elements of adherence is the nature of the patient-physician 
relationship. In large part, this is due to the quality of communication fostered by the 
physician, and the ability of this communication to cultivate trust. A strong association 
between the quality of the patient-physician relationship and medication adherence in 
general has been demonstrated. This has been associated with adherence to glaucoma 
medications as well. (Nordmann et al., 2010) Strengthening communication and the patient-
physician bond is the cornerstone of a variety of approaches for improving adherence. 
4. Objective measurement of adherence 
Several methods have been used to objectively measure adherence, in conjunction with 
subjective patient self-reports. Large insurance-claims databases are frequently used to 
gauge patient behavior, but they have been found to contain numerous errors and fail to 
accurately identify important prescribing information. (Schwartz and Quigley, 2008; 
Friedman et al., 2007; Quigley et al., 2007) Similar inconsistencies plague pharmacy refill 
data, which have difficulty distinguishing between adding a second medication and 
switching to a different medication altogether. (Friedman et al., 2007; Schwartz and Quigley, 
2008) In a large study of adherence and persistence in glaucoma patients (GAPS), chart 
review from an insurance-claims database was used in conjunction with patient telephone 
survey and pharmacy refill data to demonstrate the accuracy of the claims database in 
identifying the specific eye drops that were prescribed. However, numerous inaccuracies 
with regard to treatment history and clinical measurements were identified in the patient 
charts. (Quigley et al., 2007; Friedman et al., 2007) 
The emergence of electronic monitoring devices has aided the objective measurement of 
adherence in the research setting, however, their use may only be feasible with smaller 
numbers of patients due to cost constraints. (Schwartz, 2005). Electronic monitoring devices 
measure the opening of each bottle and are applicable to use with single and multiple 
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medication regimens. In an open-label study of OAG or ocular hypertension patients by 
Robin et al., which compared adherence rates in patients on monotherapy (once daily 
prostaglandins, n = 31) versus patients taking 2 medications (once-daily prostaglandins plus 
an adjunctive topical hypotensive medication, n = 31), where the second medication and its 
dosing regimen varied by patient, adherence rates differed between the 2 groups. (Robin et 
al., 2007) While the monotherapy group with once-daily dosing had a 90% adherence rate 
(up to 5 dosing errors allowed), adherence to the second medication in the 2-drug group 
was significantly worse (63% adherence rate). Several studies have utilized electronic 
monitoring, confirming discrepancies between physicians’ estimates and patients’ reports of 
adherence. (Okeke et al., 2009a; Friedman et al., 2009) 
The Eye-Drop Satisfaction Questionnaire was also recently developed to identify poorly 
adherent glaucoma patients by self-report. (Nordmann et al., 2010) The questionnaire 
measures 6 domains of satisfaction: treatment concern, disease concern, patient-clinician 
relationship, positive beliefs, treatment convenience, and self-declared compliance. In all 
cases of nonadherence, a poor patient-physician relationship was identified as a strong 
indicator of risk. The researchers recommended exploring this component of care before 
switching glaucoma medication or recommending laser treatment or surgery. 
5. Methods for improving adherence 
Since most glaucoma patients are initially managed with medical therapy, their ability to 
adhere to the prescribed treatment is essential for preventing disease progression. Yet, as 
mentioned, numerous factors interfere with adherence. A recent study of 253 glaucoma 
patients revealed the techniques and habits people adopted to administer their eye drops. 
(Tsai et al., 2007) While 17% relied on others to instill their drops due to poor vision or 
trouble with dexterity, among those who self-administered, 16% used a mirror. The most 
common location for administering their drops was the bedroom (47%), followed by the 
bathroom (23%) and kitchen (16%). Nearly 16% routinely failed to wash their hands before 
doing so. This type of information is important for clinically addressing individual patterns 
and habits that can improve adherence. For example, those who frequently forget to take 
their drops might benefit from visual reminders in their usual location so that administering 
drops becomes integrated into their normal routine. More patients may benefit from the use 
of a mirror, and all patients should be reminded to wash their hands. Taking more care to 
address these issues during office visits can help improve adherence. Nearly half of patients 
in one study indicated that they required more information on the correct administration of 
eye drops. (Olthoff et al., 2009) Successfully improving adherence will likely require a multi-
pronged approach that is individually tailored for each patient. Several recommendations 
have been made to overcome the different potentialities for nonadherence. (See Table 2) 
As mentioned earlier, GAPS was a very large study of adherence patterns. (Quigley et al., 
2007; Friedman et al., 2007; Tsai, 2009) Among the 8 variables identified as being 
independently associated with poor adherence, a few were somewhat surprising: relying on 
one’s physician as the sole source of information about glaucoma, not believing that reduced 
vision is a risk of poor adherence, not acknowledging stinging and burning effects, and not 
receiving a pre-visit reminder phone call. These findings highlight the notion of the patient-
physician relationship as a partnership, and emphasize the importance of the patient’s 
active involvement in their treatment by obtaining knowledge from sources other than their 
physician. Passive patients are likely to not be using their eye drops. (Tsai, 2009) Even some 
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complaints about side effects are considered good indicators of adherence. Ironically, 
stinging and burning are associated with good adherence, in as much as they indicate 
patients are taking their drops. On the other hand, hyperemia is associated with both poor 
adherence and poor persistence. (Friedman et al., 2008) 
There are several potential roles for physicians in improving adherence, although many 
clinicians currently lack the skills necessary to identify nonadherent patients and the cause 
of their nonadherence, as well as the ability to promote changes that improve adherence. 
(Quigley, 2008) Indeed, many physicians remain unaware of the pervasiveness of 
nonadherence, underestimating its prevalence as 0% to 25% when the actual rate is 24% to 
80% (Stewart et al., 2004; Rotchford and Murphy, 1998; Gurwitz et al., 1993; Patel and 
Spaeth, 1995; Olthoff et al., 2005) Moreover, they have difficulty identifying nonadherence in 
specific patients. (Okeke et al., 2009a) 
Systemic hypertension is a chronic, asymptomatic condition analogous to glaucoma in 
which physicians have successfully helped patients improve adherence. Avenues include 
those that are currently being explored for the glaucoma population, such as simplifying 
medication regimens, lowering costs, and educating patients. (Budenz, 2009) Some of the 
most successful programs motivate patients, or pair medication administration with another 
daily activity (such as brushing one’s teeth) to serve as a habitual reminder. While there is 
general agreement among patients and physicians that once-daily dosing would increase 
adherence, there remains a need for better education of patients about how to administer 
their eye drops. For example, only half of patients on multiple medications recall having 
been told to wait at least 5 minutes between instilling different medications. (Stewart et al., 
2004) One Australian study demonstrated that even patients who have been on therapy for 
over one year are likely to benefit from educational interventions that reinforce good 
administration techniques. (Curtis et al., 2008) A Norwegian study found that despite 
patient satisfaction with instructions and education, patients’ knowledge about glaucoma 
was weak, and 20% missed information. (Odberg et al., 2001) 
Hahn has identified 3 patient-centered strategies for helping physicians detect and address 
patient adherence to glaucoma medication, recognizing that patients naturally want their 
physicians to see them as good patients. (Hahn, 2009) The first strategy is a 4-step adherence 
assessment interview that redefines the good patient as someone who works collaboratively 
with their physician to overcome the normal barriers to adherence, rather than as someone 
who adheres to treatment. By inquiring about what the patient understands about their 
medication regimen, and explaining how difficult taking medications can be, how common 
nonadherence is, and that treatment decisions depend on truthfully knowing whether 
patients have adhered to their medications, the physician creates a bond of trust and 
acceptance with the patient around the topic of adherence. Patients are helped to 
understand that if IOP is too high, for example, the physician needs to know whether this is 
due to nonadherence or an inadequate medication regimen. Finally, the physician asks 
directly about adherence, after a trusting and nonjudgmental relationship is established, to 
accurately assess clinical findings and address together, with the patient, obstacles to 
adherence. Other strategies for improving adherence identified by Hahn include 
motivational interviewing techniques and an “ask-tell-ask” dialogue approach. (Hahn, 2008; 
Quigley, 2008; Boyle et al., 2005)  Motivational interviewing has been used successfully by a 
glaucoma educator in a busy ophthalmology practice to improve both motivation and 
adherence. (Cook et al., 2010) 
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Electronic monitoring of drops administration is not only reserved for research studies, but 
can help patients improve adherence in the clinical setting. Conventional bottles of eye 
drops can be equipped with the recently developed Travatan Dosing Aid (Alcon 
Laboratories, Inc., Fort Worth, TX), a miniature monitoring device that records the time and 
day when the lever that administers the medication is depressed. (Hermann et al., 2010; 
Friedman et al., 2009; Okeke et al., 2009a) Different patterns of adherence behavior can be 
identified from the downloaded data, and it was accurate in 93% in patients. (Friedman et 
al., 2007) While the majority of patients found it made dispensing drops easier, it also 
contains a reminder that can help increase adherence. This device was shown to increase 
adherence by 35% in a recent study of glaucoma patients taking PGAs, when used in 
conjunction with an educational intervention and reminders. (Okeke, 2009b) Electronic 
monitoring can be used with patients who are trying to improve their adherence, and are 
likely to increase their adherence because they know they are being monitored, potentially 
habituating them to integrate taking eye drops into their usual routine. The devices can also 
be used in specific patients when physicians need to monitor adherence, to inform clinical 
decision making in those patients. They can be used in conjunction with reminders and with 
timers equipped with audible or visual signals. Reminders and recall systems can send 
messages or emails to cell phones, reminding patients to instill their drops or alerting them 
to upcoming office visits. (Kowing et al., 2010) While electronic monitoring is a more 
accurate way of recording whether an eye drop is dispensed at the appropriate time, it is 
unable to assess whether the drop was correctly instilled into the eye and was utilized. 
However, enhanced educational efforts can address this. 
Low health literacy also contributes to poor adherence. (Tsai, 2009; Kholdebarin et al., 2008) 
In the clinical setting, it is necessary to be attentive to this and compensate by educating 
patients about the importance of adherence, demonstrating the method of instillation, and 
observing how patients actually administer their eye drops. (Muir et al., 2006) Providing 
written instructions also has been shown to dramatically improve adherence in patients 
with poor health literacy. In an intervention study to improve the adherence of glaucoma 
patients with poor health literacy, only 42% of patients who did not complete high school 
were initially able to accurately answer questions about their medications, compared with 
79% of patients who had completed high school. (Kharod et al., 2006; Tsai et al., 2009)  After 
receiving written instructions about their medication regimen, 88% of patients in the former 
group and 96% of patients in the latter group were able to accurately answer questions 
about their treatment. Different types of educational programs have been designed to 
enhance patient knowledge. Provision of a 2-hour information session was received well by 
patients, and holds the potential to increase adherence. (Blondeau et al., 2007) 
Knowledge about side effects and the importance of adherence is lacking in many patients, 
regardless of health literacy. (Odberg et al., 2001) Hyperemia is one of the side effects of 
prostaglandins that can significantly reduce adherence and persistence. A multicenter, 
randomized patient education program on hyperemia associated with bimatoprost therapy 
was provided to 106 patients in an effort to encourage patients to continue using their 
medication in order to lower IOP. Patients in the educational intervention arm were 
significantly (P < .003) more likely to be willing to continue using bimatoprost despite the 
hyperemia, and were also more likely to report that IOP lowering was important for 
preserving vision (98% vs. 76%, P < .001). (Trattler et al., 2008) 
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Medication-Related Methods 
Medication that uses once-daily dosing regimen 
Use of fixed-dose combination regimens 
Use of a dosing aid 
Patient-Related Methods 
Improve instillation technique 
Integrate eye drops administration with daily routine 
Adhere to office visits 
Physician-Related Methods 
Improve the patient-physician relationship 
Show understanding about the difficulty of adherence 
Provide patient education about the role of drops in preventing blindness 
Provide instruction about the proper instillation of drops 
Give the patient written instructions 
Observe the patient’s instillation technique at several visits 
Have an honest discussion with the patient about adherence 
Discuss cost issues with the patient 
Find out what specifically is interfering with the patient’s adherence 
Give reminder phone calls before office visits 
Give reminder phone calls about administering drops 
Redefine a good patient as one who wants to work with their physician to understand 
adherence challenges in a nonjudgmental manner 
Use electronic monitoring of drops administration 
Table 2. Methods for Improving Adherence 
6. Association between adherence and the use of specific glaucoma 
medications 
Simplified regimens that only require once- or twice-daily dosing or use of fixed 
combination dosing can potentially improve adherence. A study that queried patients’ 
preferences for dosing frequency on a 10-point visual analogue scale significantly favored 
once daily regimens over 2, 3, or 4 doses daily. (Buller et al., 2007) 
In studies of adherence to glaucoma medications, the PGAs have the highest adherence rate, 
due to their once-daily dosing and low side-effect profiles. (Djafari et al., 2009) However, 
even this best-case scenario only has an adherence rate of 70%, comparable to that of oral 
hypertension medications. (Quigley et al., 2007) A retrospective, 12-month study of a large 
employer-based health plan database that compared pharmacy claims for PGA 
prescriptions, in which glaucoma patients were persistent during the first 90 days of 
therapy, demonstrated that the mean number of days that patients were adherent with 
bimatoprost therapy (291.2 days) was significantly higher than for latanoprost (281.0 days), 
and similar to that of travoprost (287.0 days). (Wilensky et al., 2006) The mean adherence 
rate for the study was 76%, indicating that opportunities remain for improving adherence 
for glaucoma medications. 
Due to the greater complexity of using multiple glaucoma medications in patients 
inadequately responsive to monotherapy, fixed-combination drops offer advantages. In 
addition to simplifying the dosing regimen and reducing the number of bottles and 
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instillations, they eliminate the need for waiting between instillations, reduce the amount of 
preservative delivered to the eye, and offer potential cost savings. (Higgenbotham, 2010) 
Their convenience likely increases adherence, which is especially important at a time when 
visual detriments are clinically evident or IOP is suboptimally controlled. The availability of 
fixed-combination topical glaucoma medications dates back to the 1960s, however, few 
combinations had been developed because of insufficient potency, the potential for drug 
interactions, and different pharmacokinetics. (Khouri et al., 2007) Once the ǃ-adrenergic 
antagonist timolol became available as first-line treatment, its dosing regimen was more 
compatible with several other classes of topical glaucoma medications. Theoretically, the 
greatest beneficial effect would likely be achieved by combining agents that affect both 
aqueous humor inflow and outflow: for example, use of timolol, which is an inflow 
suppressant, in combination with outflow-enhancing medications such as the PGAs. 
(Woodward and Chen, 2007; Clark and Yorio, 2003) Typically, PGAs may be used in 
combination with either beta-blockers, carbonic anhydrase inhibitors, or alpha-adrenergic 
agonists. (Tabet et al., 2008) Fixed-combination treatments currently available include 
timolol 0.5% in combination with either brimonidine 0.2%, dorzolamide 2%, travoprost 
0.004%, latanoprost 0.005%, or bimatoprost 0.03%. (Tabet et al., 2008; Higgenbotham, 2010) 
Whether combination therapy delivers on its promise of greater clinical benefit and 
increased adherence and persistence due to enhanced convenience and tolerability was the 
focus of a recent study by Dunker et al. (Dunker et al., 2007) Patients who were switched to 
combination therapy with latanoprost/timolol were followed for 6 months and given a 
quality-of-life questionnaire. Of the 1,052 patients, 71% had switched from multi-bottle 
therapy, and 29% had switched from monotherapy. In 71%, the reason for the switch was 
due to insufficient IOP reduction with the previous therapy, while in 66% the reason was to 
simplify to once-daily administration. Throughout the follow-up period, 97% remained on 
therapy. By self-report, after switching therapy patients were less likely to forget to instill 
their drops or to complain of adverse effects. Overall, they were more satisfied with the 
frequency of instillation, and they found it easier to include taking the drops in their daily 
routine. Mean IOP in the 6-month period decreased by 14.8% to 17.2 mm Hg. Another study 
that compared combination treatment with brimonidine 0.2%/timolol 0.5% to dorzolamide 
2%/timolol 0.5% in alternate eyes of normal-vision subjects without ocular disease found 
that brimonidine/timolol (favored by 80%) provided significantly less ocular discomfort 
than dorzolamide/timolol (10%) (P < .00001). (Chan et al., 2007) 
7. Persistence rates for glaucoma medications 
Rates of persistence with glaucoma therapies are substantially lower than rates of 
adherence, ranging between 20 and 64%. (Schwartz and Quigley, 2008) Studies have 
attempted to account for the reasons for poor persistence. The use of glaucoma drops is a 
lifelong commitment, which patients must accept to preserve their vision. Factors that 
contribute to poor persistence differ somewhat from those attributed to poor adherence. 
Poor persistence is closely associated with poorly attended follow-up visits; high cost and 
low health literacy are also significant barriers. (Schwartz and Quigley, 2008) Jayawant et al. 
demonstrated that depression is significantly (P < .005) associated with reduced glaucoma 
medication persistence, especially in patients who live alone. (Jayawant et al., 2007) 
Studies of persistence in a managed care organization revealed that more than one-half of 
patients failed to renew their initial prescription of glaucoma eye drops by one year after 
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diagnosis. (Fiscella et al., 2003) Even more telling, when cost was not an issue among 
participants in a U.S. government health plan, 25% of newly diagnosed POAG patients 
never renewed their initial prescription. (Gurwitz et al., 1993) The introduction of 
latanoprost as an IOP-lowering agent with once-daily dosing was associated with improved 
persistence (75%) in a large study of treatment-naïve Medicare enrollees. (Bhosle et al., 2007) 
One way to evaluate persistence is referred to as gap analysis because it examines patients 
who persisted with therapy over a 12-month period, with intervening gaps when the 
medication was not refilled. In a study by Lee et al. that analyzed pharmacy claims data in a 
large retail pharmacy database for 2.5 mL bottles of PGAs, 3 separate gap lengths were 
analyzed that spanned periods in excess of 45, 60, or 120 days without a refill. (Lee et al., 
2007)  Patients were categorized based on the number of gaps in therapy and the cumulative 
length of the gaps. For refill periods of 45, 60, or 120 days, 10.6%, 28.6%, and 77.5% of 
patients, respectively, had no gaps in therapy. In addition, 32.6%, 53.4%, and 86.5% of 
patients, respectively, had 30 days or less off therapy. According to the Kaplan-Meier curve, 
a total of 88.6% of patients were persistent for 120 days, and 76.1% of patients were 
persistent for one year. The gap analysis was a more realistic appraisal of true persistence, in 
which patients stop and restart medications over time. 
Another analysis was performed in Australia using pharmacy claims data to examine 
resupply rates for topical glaucoma medications over a 12-month period. (Franzco JLR, 
Adena MA. 2007) Gap lengths of 60, 90, and 120 days were allowed. Researchers 
demonstrated that patients taking PGA therapy (bimatoprost [53% persistence], latanoprost 
[52% ], and travoprost [42%]) or fixed-combination therapy with dorzolamide/timolol (55%) 
had the highest persistence rates one year after initiating therapy. 
In an attempt to determine the cause of nonpersistence, Zimmerman et al. examined the 
association between ocular adverse effects of certain topical glaucoma medications, changes 
in prescription patterns, and rates of persistence. (Zimmerman et al., 2009) Using a 
pharmacy claims database, patients’ medical charts, and telephone interviews with patients 
and physicians, they found that persistence rates for continuous refills of the PGAs  were 
11% for latanoprost, 9% for bimatoprost, and 5% for travoprost. The most common reason 
for switching medications was lack of efficacy (43%), followed by adverse effects (19%). 
Adverse effects were noted in 65% of patients’ charts, with hyperemia (48%) being the most 
common. In general, therapy-naïve patients have a higher risk of discontinuing medication 
during the first 30 days of therapy than medication-experienced patients, and this is 
especially true for non-oral medications such as glaucoma eye drops, asthma inhalers, and 
diabetes insulin injections. (Vanelli et al., 2009) 
8. Parameters that affect instillation 
The patient’s technique for instilling eye drops is critical to medication effectiveness. Factors 
such as whether the drop actually enters the eye, whether the tip of the bottle touches the 
eye, and whether 1 or 2 drops are released from the bottle, can both increase cost and alter 
effectiveness. While many patients lack dexterity or have visual deficits that interfere with 
instillation, proper instillation technique and instructions must be conveyed in a manner 
that is reproducible in the patient-use setting. (see Table 3) 
Many patients are not aware of the fact that they are instilling the medication incorrectly. 
Videotaping the instillation process has been very telling in this regard. When medication-
experienced glaucoma patients were videotaped to evaluate their instillation technique, only 
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71% were able to get a drop onto the ocular surface, and only 39% were able to do this 
without touching the eye with the tip of the bottle. (Hennessy et al., 2010) Fully 24% of 
patients who denied touching the bottle to the ocular surface were shown to have 
contaminated the tip. Advanced patient age was the only significant predictor for less 
successful instillation. 
In one study of patients over the age of 75, less than one-third of the patients instilled the 
drops themselves. (Burns and Mulley, 1992) In addition to visual and dexterity limitations, 
many elderly individuals experience shoulder limitations that make it difficult for them to 
lift the bottle over the eye. Of those who did instill their own drops, half were unlikely to 
successfully instill the drop into the conjunctival sac, yet few patients had been prescribed 
aids or devices to improve their technique. 
Consequently, efforts have been made to better understand the instillation process, to 
change the formulation of the drops so as to alter their instillation properties, and to develop 
physical aids that can assist the patient in delivering the drug. In actuality, the most efficient 
instillation technique varies with both the formulation and the bottle from which the drop is 
delivered. The size of the drop is determined by physical properties of the solution, 
particularly the viscosity and surface tension. Drop size also depends on the design and 
dimensions of the dropper tip and the angle of the bottle when the drop is dispensed. (Van 
Santvliet and Ludwig, 2004) A recent study compared the number of drops that were 
dispensed from 2.5 mL bottles of latanoprost, bimatoprost, and travoprost, when the bottles 
were held vertically, horizontally, or at a 45-degree angle. (Fiscella et al., 2006) For all 3 
drugs, the mean number of drops dispensed from a 25 mL bottle differed substantially 
when dispensed at different angles. For bimatoprost, the mean number of drops dispensed 
when the bottle was held vertically, at 45 degrees, or horizontally was 111.0, 105.1, and 76.1, 
respectively. Due to the specific shape and size of the tip, the greatest number of drops was 
dispensed in the vertical position. For latanoprost, the mean number of drops was 94.3, 88.4, 
and 67.1, respectively. For travoprost, the mean number of drops was 81.4, 101.1, and 85.3. 
Thus, latanoprost also produced more drops in the vertical position, while travoprost 
produced the greatest number of drops when held at a 45-degree angle. 
The differences are significant and contribute to cost. To make a cost determination, this 
information must be combined with the mean volume of medication dispensed per 2.5-mL 
bottle, which was 3.17 mL for bimatoprost, 3.02 mL for latanoprost, and 2.54 mL for 
travoprost. In all, the most efficient instillation method for each medication provided 56 
days of bilateral therapy for bimatoprost, 47 days for latanoprost, and 51 days for 
travoprost. This yields yearly medication costs of $408 for bimatoprost, $475 for latanoprost, 
and $449 for travoprost. 
The volume of the drop dispensed into the eye varies with the medication, but in most cases 
exceeds the volume that the palpebral fissure can accommodate, which is 30 μL. (Van 
Santvliet and Ludwig, 2004) Since normal tear volume is 7 μL-10 μL, the volume available 
for instillation is 20 μL-23 μL. Smaller size drops, on the order of 15 μL, have an efficacy and 
bioavailability equivalent to larger drops, without the waste. In fact, drops of this size are 
preferable, as they minimize systemic exposure and wastage. 
To help less adept patients instill their drops properly, different types of delivery devices 
have been developed. One such delivery device, Xal-Ease, holds the bottle, helps the patient 
position it over the eye, and then releases exactly 1 drop into the eye. A prospective, 
randomized, comparative crossover study of 211 French POAG patients measured the 
impact of Xal-Ease on patient satisfaction and adherence compared to the regular dropper 
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bottle in the same group of patients. (Nordmann et al., 2009) Patients used one delivery 
method for 4 weeks, and then switched to the other delivery method. Use of Xal-Ease 
decreased patients’ reliance on others to administer their eye drops (6.9% with Xal-Ease vs. 
18% with the dropper bottle), increased the frequency of both delivering drops into the eye 
(43.1% vs. 26.7%) and of only dispensing 1 drop (52.4% vs. 23.5%), and reduced the 
frequency with which the bottle tip touched the eye (35.6% vs. 3.2%). More than 71% of 
patients reported being very satisfied with the device, although adherence was high and 
similar for both groups (95.8-97.8%). 
Efforts also have been made to alter the formulation of glaucoma medications in a variety of 
ways, beginning with changing or removing the type of preservative used, because many 
ocular surface side effects have been attributed to benzalkonium chloride, the most 
commonly used preservative in topical medications. Direct comparison of eye drops with 
and without preservatives have demonstrated the disappearance of most symptoms in 
preservative-free drops. (Pisella et al., 2002) Alternate preservatives, such as Purite and 
Sofzia, have been used with formulations of brimonidine and travatan. However, in studies 
comparing the different available preservatives, only benzalkonium chloride/EDTA met the 
European Pharmacopoeia criteria for preservative efficacy. (Ghate and Edelhauser, 2008) 
Another strategy to lessen side effects is to lower the concentration of the active ingredient. 
This was recently done successfully with bimatoprost with the introduction of a formulation 
with a .01% concentration rather than the original .03% concentration of active ingredient. 
Hyperemia was significantly reduced without reducing efficacy. (Katz 2010, Craven 2010) 
It is not uncommon for the physicochemical properties of the drug to be changed in order to 
increase its bioavailability. Drug penetration across the corneal epithelial barrier is 
facilitated by lipophilic, rather than hydrophilic molecular properties. (Ghate and 
Edelhauser, 2008) These considerations were essential for the development of both the 
topical carbonic anhydrase inhibitors and the PGAs. Due to the severe ocular irritation 
associated with the naturally occurring prostaglandins, changes were made to the molecule 
itself to reduce hyperemic effects, and led to the development of latanoprost. (Ghate and 
Edelhauser, 2008) Other topical medications that have solubility problems, such as betaxolol 
and brinzolamide, can be delivered to the eye as suspensions. However, drugs in 
suspension have the disadvantage of needing to be resuspended before use by shaking, 
which reduces the medication adherence rate. (Ghate and Edelhauser, 2008) 
 
Patient dexterity 
Patient vision 
Ability of patient to lift arm above eye 
Whether a mirror is used as an aid 
Whether drops are dispensed into or onto the eye 
Whether only one drop is dispensed 
Whether the bottle tip touches the eye 
Shape and dimensions of the bottle tip 
Viscosity and surface tension of the drops solution 
Table 3. Parameters that Affect Drops Instillation 
Several different formulations have been developed that increase the viscosity of ocular 
medications, thereby enhancing absorption by increasing the residence time in the 
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conjunctival sac. All have been developed with the intent of facilitating drug delivery and 
increasing adherence rates. Gels are semisolid formulations that increase retention time and 
allow for once-daily dosing, although ocular side effects are higher than with solutions. 
(Ghate and Edelhauser, 2008) Novel gel formulations are delivered as a liquid which, when 
triggered in situ by pH or temperature, form a gel. (Gupta et al., 2007; Nanjawade et al., 
2007) Timolol and pilocarpine are available in gel formulations. 
In addition to new formulations, other methods have been developed to provide more 
efficient delivery of ocular medications to specific ocular tissues, thereby increasing 
adherence and persistence. Ocular inserts are solid devices that are placed in the 
conjunctival sac to release medication at a constant rate over a prolonged period. (Ghate and 
Edelhauser, 2008) They have the advantage of minimizing systemic absorption through the 
nasal mucosa and improving adherence. In addition to a pilocarpine insert (Ocusert, [Alza 
Corp]) several other types of inserts are being developed, including medicated contact 
lenses, erodible inserts, and collagen shields. (Ghate and Edelhauser, 2008; Vold and 
Buznego, 2010; Jain et al., 2010) Punctal plugs elute PGAs from a core in the plug, however 
the retention rate of the plug within the eye still requires improvement. (Vold and Buznego, 
2010) Ocular implants can be placed in the sclera, subconjunctiva, intravitreal, or 
suprachoroid, and can be biodegradable or nonbiodegradable. (Short, 2008; Bourges et al., 
2006; Choonara et al., 2009; Yasukawa et al., 2006) Miniaturization of the implants facilitates 
their delivery by direct injection. Medications can also be delivered by periocular injection, 
to facilitate drug delivery to the posterior segment of the eye, however repeated long-term 
injections can cause serious ocular complications. (Ghate and Edelhauser, 2006; Myles et al., 
2005)  A more recent innovation is encapsulated cell technology which promises long-term 
sustained drug delivery via cells engineered to manufacture the drug that are encapsulated 
in a semipermeable hollow fiber membrane. (Tao, 2006) 
Several other approaches to increasing retention time in the conjunctival sac are being 
developed. (Ghate and Edelhauser, 2008)  Microspheres composed of chitosan are used to 
enhance delivery of pilocarpine, and delivery of timolol has been sustained for 3 months 
using microspheres. (Bertram et al., 2009) Biodegradable microspheres are also available. 
(Herrero-Vanrell and Refojo, 2001) Nanoparticles and their derivatives are polymeric 
macromolecular colloids used to entrap, dissolve, encapsulate, or adsorb the medication. 
They are under investigation as nanospheres, in which the drug is in the matrix or adsorbed 
to the surface of colloidal carriers, or as nanocapsules. All are intended to increase retention 
time in the corneal sac and enhance penetration through the corneal and conjunctival 
barriers. (Barbu et al., 2009; Bourges et al., 2003; Wadhwa et al., 2009) Liposomes, a type of 
nanosphere, are microscopic spheres of lipid bilayers designed to circumvent cell membrane 
barriers that are being investigated for application in glaucoma medications. Liposomes are 
designed to be injected into the eye, and offer the advantage of reduced toxicity since a 
limited amount of drug is in contact with ocular tissues. (Short, 2008) 
9. Cost is an essential consideration 
Cost is a key consideration when comparing glaucoma medications, both for its effect on 
patient adherence and persistence, and as a priority when selecting which medication to 
use. Patients are often reluctant to raise the issue of cost with their physician, but the 
physician should proactively initiate a cost conversation, particularly when multiple 
medications are required. In an effort to reduce costs by extending the duration of the 
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prescription, patients may use their drops more sparingly than is effective, unintentionally 
reducing health outcomes. 
Given that direct costs of glaucoma increase with disease severity, glaucoma treatment that 
delays disease progression can significantly reduce the health economic burden of 
glaucoma. (Lee et al., 2006; Fiscella et al., 2009) Medication costs are the largest contributor 
to direct costs of glaucoma. (Lee et al., 2006; Traverso et al., 2005; Lindblom et al., 2006) 
Several different types of pharmacoeconomic analyses have been conducted on glaucoma 
medications. Cost minimization represents one of the simplest types, directly comparing 
medication costs based on utilization. Cost-effectiveness analysis additionally factors utility 
into the cost equation. 
PGAs are favored for their effectiveness at lowering IOP and their once-daily 
administration. Since the budgetary impact of long-term therapy with glaucoma medication 
contributes to medication decision making by patients, physicians, and insurers, we 
conducted a study was conducted to compare the relative value of PGAs with respect to 
prescription duration and refill rates. (Walt et al., 2007) A retrospective analysis of 
dispensing patterns for the 2.5-mL bottle of latanoprost, bimatoprost, and travoprost in 
patients persistent for at least one year using a large retail pharmacy database revealed that 
the mean number of days between prescription refills was significantly (P < .00001) different 
for the 3 medications, and was longest for travoprost: 46.74 days for latanoprost, 51.98 days 
for bimatoprost, and 53.65 days for travoprost. The mean number of refills per year was 7.1, 
6.4, and 6.2, respectively. Based on this analysis and the average wholesale price of each 
drug, the average annual cost per patient for each medication was $US435.16 for 
latanoprost, $US397.44 for bimatoprost, and $US385.58 for travoprost. 
However, the effectiveness of each drug in reducing IOP must also be taken into 
consideration. In an analysis of the PGAs, bimatoprost was found to be the most cost 
effective because it provided the greatest IOP reduction, as reported in the literature. 
(Noecker and Walt, 2006) While the average wholesale price of a 2.5-mL bottle of 
latanoprost, bimatoprost, and travoprost was $61.29, $62.10, and $62.19, respectively, the 
average IOP reduction for each was 29.6%, 32.4%, and 29.0%, respectively. Based on these 
figures, the calculated cost-effectiveness for each drug was $2.07 for lanatoprost, $1.92 for 
bimatoprost, and $2.14 for travoprost. 
In two related analyses, a higher percentage of patients achieved their target IOPs with 
bimatoprost than with the other PGAs, resulting in a significantly higher rate of treatment 
success with bimatoprost. (Goldberg and Walt, 2006; Fiscella and Walt, 2006) As a result, the 
cost-per-treatment success was $568 lower with bimatoprost ($1,501/success) compared to 
latanoprost ($2,069/success). (Fiscella and Walt, 2006) A paired-eye comparison of 
bimatoprost in one eye and travoprost in the other eye demonstrated that bimatoprost 
yielded greater IOP reduction (2.7 mmHG vs. 1.7 mmHG). (Solish et al., 2010) Patients chose 
to continue therapy with bimatoprost rather than travoprost by a factor of 2.4 to 1, primarily 
due to the greater IOP reduction of bimatoprost. A Markov model pharmacoeconomic 
analysis comparing bimatoprost and filtration surgery also demonstrated the superiority of 
bimatoprost in achieving lower costs by delaying the need for filtration surgery by 4 years in 
34% of patients, and by 1 year in 64% of patients. (Christensen et al., 2005) 
Two cost minimization studies also were conducted. The first compared the cost of PGAs 
alone in newly diagnosed glaucoma patients using pharmacy data. (Schmier et al., 2007)  In 
over 4,000 patients studied, the average number of days until beginning adjunctive therapy 
for those patients who did not achieve optimal outcomes with PGAs alone was 104 days for 
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latanoprost, 94 days for bimatoprost, and 130 days for travoprost. Average annual costs 
were $1,217, $1,290, and $1,198, respectively. In a second cost minimization study, the daily 
patient cost for each type of glaucoma medication was calculated, based on the actual fill 
and overfill volumes in the 2.5-mL bottles (unless otherwise specified). (Fiscella et al., 2003) 
The tips of several of the bottles had been recently redesigned. Included in the calculations 
were the number of drops per mL, which can differ based on the dimensions of the tip of the 
bottle, and also vary with the viscosity and surface tension of the solution. Generic timolol 
had daily costs (range $0.38-$0.46 per day) that were similar to the branded Betimol (Santen, 
Napa Valley, CA), Optipranolol (Bausch and Lomb Pharmaceuticals, Tampa, FL), and 
Timoptic (Merck, West Point, PA). Timoptic is available in a new ergonomic bottle, the 
Ocumeter Plus. The 5 mL bottles of the topical ǃ-blockers Betagan (Allergan, Irvine, CA), 
Betoptic S (Alcon Laboratories, Fort Worth, TX), and Ocupress (Novartis, Duluth, GA) 
ranged between $0.88 and $1.11 per day. Mean costs per day for the 5 mL bottles of topical 
carbonic anhydrase inhibitors were $1.33 for Azopt (Alcon Laboratories) and $1.05 for 
Trusopt (Merck). The alpha-2 agonist brimonidine 0.15% with Purite, (Alphagan-P, 
Allergan) in the 5 mL size dispensed twice daily, was $1.29 per day. The 4 PGAs Lumigan 
(Allergan), Xalatan (Pharmacia and Upjohn, Kalamazoo, MI), Travatan (Alcon Laboratories), 
and Rescula 5 ml (Novartis) were priced at $0.95, $1.25, $1.01, and $0.90 per day, 
respectively. The combination medication Cosopt (Merck), which combines timolol 0.5% 
plus dorzolamide 2% in a 10 mL bottle, was priced at less than the cost of separate bottles of 
a ǃ-blocker and a carbonic anhydrase inhibitor. Thus, the assumption that the higher priced 
bottle costs more per day is not always correct, because the product with the smaller drop 
size may last longer. 
Fixed combinations of glaucoma medications have been shown to be effective second-line 
treatment for glaucoma. Direct comparison of fixed combinations of brimonidine 
0.2%/timolol 0.5% and dorzolamide 2%/timolol 0.5% were compared to individual 
adjunctive dosing of each of the drugs in the combination. (Hommer et al., 2008)  The fixed 
combination prescriptions were found to be equally as effective as when the 2 individual 
drugs were used as adjunctive therapy. The fixed combination of brimonidine/timolol was 
less expensive than dorzolamide/timolol. Results were somewhat different in another study 
in which patients on adjunctive combination therapy with dorzolamide and timolol were 
switched to a fixed combination of the 2 drugs. Compared to the separate dosing, the fixed 
combination was more effective, further reducing the IOP by 1.5 mmHg, which was 
attributed to improved adherence with the fixed combination. (Gugleta et al., 2003) 
10. Future direction of glaucoma therapy 
While lowering IOP is the only therapeutic strategy proven to limit progression of 
glaucoma, several other approaches are being explored for their potential to directly reduce 
deterioration of the optic nerve head. Chief among these are the use of agents that can act as 
neuroprotectants. (Cheung et al., 2008) Several strategies for neuroprotection are 
conceivable including slowing the death of retinal ganglion cells and enhancing blood flow 
to the optic nerve. (McKinnon et al., 2008) These would be used in conjunction with topical 
agents currently used to lower IOP. (McKinnon et al., 2008; Quigley, 2005) Oral medications 
that provide neuroprotection act by blocking N-methyl-D-aspartate (NMDA)-sensitive 
glutamate receptors. These include memantine, an NMDA receptor blocker currently 
approved for treatment of Alzheimer’s disease, and riluzole, a glutamate regulator 
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approved for treatment of amyotrophic lateral sclerosis. (Levin, 2005; Lipton, 2004; Hare et 
al., 2004a; Hare et al., 2004b; Cheung et al., 2008; Guptd, 2005a, 2007; Greenfie) Memantine, 
however, failed to show efficacy in large scale glaucoma clinical trials. Still another 
possibility is dextromethorphan, a type of narcotic. (McKinnon et al., 2008) 
Several additional agents are being investigated for neuroprotective effects. Brimonidine, a 
selective ǂ-adrenergic antagonist currently used topically to treat glaucoma is purported to 
have neuroprotective effects in addition to its ability to lower IOP. (WoldeMussie et al., 
2001) While brimonidine’s neuroprotective effects are evident in animal studies, results in 
humans are inconclusive, although its ability to prevent progression exceeded that of 
timolol in glaucoma patients with low IOP despite the similar IOP-lowering effects of these 
medications. (Krupin et al., 2011; McKinnon et al., 2008) Glatimir, an agent that is injected 
subcutaneously in multiple sclerosis patients, is under investigation for glaucoma. 
Erythropoietin is also under investigation for its ability to promote survival of retinal 
ganglion cells. (Zhong et al., 2007) Glial cell-line derived neurotrophic factor, a glaucoma 
vaccine with Cop-1 which has been approved for multiple sclerosis, is also the focus of 
active research. (Baudouin and Liang, 2006; Ward et al., 2007) Cannabinoids are also being 
investigated for their ability to lower IOP. (Woodward and Chen, 2007) 
Pharmacologic agents are also being investigated for their ability to enhance ocular blood 
flow, another proposed, but unproven, strategy to limit glaucoma progression. 
Dorzolamide, a topical carbonic anhydrase inhibitor that lowers IOP, also has been shown to 
increase retinal artery flow velocity. Betaxolol, a ǃ-blocker currently used topically to reduce 
IOP, has also been demonstrated to increase blood flow capacity in the optic nerve head. 
(McKinnon et al., 2008) 
These combined approaches to glaucoma therapy generate great promise for preventing 
disease progression. Using them in combination with topically lowering of IOP may be the 
most effective means to manage glaucoma. However, adherence and persistence remain 
challenging, and at the present time patients and physicians need to be encouraged to work 
together to ensure the delivery of existing medications with proven effectiveness. 
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